<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01239706</url>
  </required_header>
  <id_info>
    <org_study_id>23036</org_study_id>
    <nct_id>NCT01239706</nct_id>
  </id_info>
  <brief_title>Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1</brief_title>
  <official_title>A Phase IIa, Single Centre, Open Label Study to Characterize the Safety of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stem Cell Theraputics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Open Label, Cohort Study in Traumatic Brain Injury Patients. The goal of this
      study is to assess the safety of NTx®-265. NTx®-265 will be administered over 9 days, and
      patients will be followed for an additional 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint for this study is safety. The following safety endpoints will be assessed:
Type, incidence, severity, timing, seriousness, and relatedness of adverse events.
Lower extremity deep vein ultrasound will be performed to identify and localize deep or superficial venous thrombosis.
Vital signs
Laboratory assessments. Particular attention will be paid to serial hemoglobin and hematocrit measurements.
DVT, PE, thromboembolism, MI and stroke.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>The following secondary endpoints will also be assessed in order to measure various aspects of neurological status:
GOSE at hospital discharge, 3, and 6 months post-TBI
Neurobehavioral Rating Score at hospital discharge, 3, and 6 months post TBI
Disability Rating Score at hospital discharge, 3, and 6 months post TBI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>NTx 265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTx 265</intervention_name>
    <description>10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin</description>
    <arm_group_label>NTx 265</arm_group_label>
    <other_name>Eprex, Ortho Biotech</other_name>
    <other_name>Ovidrel, Serono</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients age 18-65

          2. Written and informed consent from a legally acceptable representative

          3. Moderate to severe traumatic brain injury (TBI) defined as Glasgow Coma motor (GCSm)
             score ≤5, post resuscitation.

          4. Patient is &lt;48hours from time of injury when the first dose of NTx™-265 is
             administered.

          5. Reasonable expectation of availability to receive the full 9 day course of therapy and
             be available for follow up evaluations

          6. Female patient is either:

               1. Not of childbearing potential, defined as postmenopausal for at least 1 year or
                  surgically sterile (bilateral oophorectomy or hysterectomy) or

               2. If of childbearing potential, would agree to use two of the following reliable
                  methods of birth control throughout the study, including the follow-up visits:

                    -  Condoms, sponge, foams, jellies, diaphragm or intrauterine device

                    -  A vasectomised partner

                    -  Abstinence

                    -  Note: Hormonal Based contraceptives are NOT permissible as one of the two
                       forms of contraceptives for this study.

        Exclusion Criteria:

          1. Women who have been tested positive for pregnancy, or are breast-feeding or are not
             using a highly effective method of birth control that can be maintained for the
             duration of the study.

          2. Bilaterally fixed pupils

          3. Serum hemoglobin &gt;160g/L (males) or &gt;140g/L (female); or platelet count &gt; 400,000/mm3

          4. Advanced cardiac, pulmonary, hepatic or liver disease; the former will be
             operationally defined using NCI Toxicity Criteria (Grade 2 or higher).

          5. Suspected anoxic or ischemic brain injury

          6. Known endocrine or germ cell tumor

          7. Serum billirubin &gt; 1.5 x upper limit of normal (ULN).

          8. Alkaline Phosphatase &gt; 2.5 x ULN

          9. AST and/or ALT &gt; 2.5 x ULN

         10. Creatinine &gt; 2.0 x ULN

         11. Patients with known or documented transferrin saturation &lt; 20% or ferritin &lt; 100ng/mL.

         12. Male patients with known and documented elevated PSA levels, or a PSA level of ≥4ng/mL
             at screening.

         13. Patients with known history or hypercoagulability, including known
             cardiolipin/antiphospholipid antibody syndrome.

         14. Allergy or other contraindication to hCG including:

               1. Prior hypersensitivity to hCG preparations or one of their excipients.

               2. Primary ovarian failure.

               3. Uncontrolled thyroid or adrenal dysfunction.

               4. An uncontrolled organic intracranial lesion such as a pituitary tumor.

               5. Abnormal uterine bleeding of undetermined origin.

               6. Ovarian cyst or ovarian enlargement of undetermined origin.

               7. Sex hormone dependent tumors of the reproductive organs, accessory sex glands,
                  and breasts.

         15. Allergy or other contraindication to epoetin alfa:

               1. Who developed pure red cell aplasia following treatment with any erythropoiesis
                  regulating hormones.

               2. With uncontrolled hypertension

               3. With known hypersensitivity to mammalian cell-derived products, albumin (human)
                  or any component of the product

               4. Who for any reason cannot receive adequate antithrombotic treatment

         16. A known diagnosis of cancer (except basal cell cancer).

         17. Uncontrolled hypertension, defined as blood pressure persistently above 220 mm Hg
             systolic or 120 mm Hg diastolic despite antihypertensive therapy.

         18. Use of either hCG or epoetin alfa within the previous 90 days.

         19. Any condition known to elevate hCG, active in the prior 24 months e.g.,
             choriocarcinoma or germ cell tumor.

         20. Any patients living in a nursing home or supervised living center. Patients must be
             historically fully independent in all activities of daily living including banking,
             shopping, cooking, toileting, showering and dressing.

         21. Any other medical condition, in the investigator's opinion, the patient should not be
             included in the trial.

         22. Patients who cannot take anti-platelet or anti-coagulant therapy.

         23. Pre-existing and active major psychiatric or other chronic Neurological disease.

         24. Patients who have a history of substance abuse or dependency within 12 months prior to
             the study.

         25. Currently participating in another investigational study

         26. Polytrauma defined as an Abbreviated Injury Severity Score &gt;3 in any area other than
             head.

         27. Patients with evidence of an active or previous thrombotic event.

         28. Patients with contraindications to MRI scans

         29. Patients who are currently taking hormonal based contraceptives or hormonal
             replacement therapy in the past three (3) months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Zygun, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Zygun, MD</last_name>
    <phone>403-944-1691</phone>
    <email>dzygun@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Todd, BSc, MBT, CCRP</last_name>
    <phone>403-944-3414</phone>
    <email>stephanie.todd@albertahealthservices.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Todd, BSc, MBT, CCRP</last_name>
      <phone>403-944-3414</phone>
      <email>stephanie.todd@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>David A Zygun, MD, MSc,</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Kramer, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clare Gallagher, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Scott, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2010</study_first_posted>
  <last_update_submitted>November 10, 2010</last_update_submitted>
  <last_update_submitted_qc>November 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. David A Zygun</name_title>
    <organization>University of Calgary</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

